ESR1 and breast carcinoma: Further, this study characterized a model looking at TNBC, however ER+HER2− patients had a statistically significantly worse OS, therefore there are likely other breast cancer patient populations with EGFR amplification and PI3K alteration who might benefit from this dual therapy (Fig. S1).